Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 12, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr. Dhavalkumar Patel as Scientific Advisor. Dr. Patel...
KPJ Healthcare Launches First Kidney Transplant Service Within Its Hospital Network
Tawakkal Specialist Hospital expands access to kidney transplantation through coordinated specialist care KUALA LUMPUR, Malaysia, June 11, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") has launched its first Kidney Transplant Service within the KPJ network, marking a significant milestone that expands access to highly specialised transplant care and reflects the continued development of advanced...
Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate Bio on the successful close of a...
Topic: Binance Commits $250,000 to Support Frontline Ebola Response in Uganda and DRC
Two of the world's most experienced emergency responders, the Uganda Red Cross Society and Doctors Without Borders, will each receive funding to strengthen medical care, prevention, and community response. JOHANNESBURG, South Africa, June 11, 2026 /PRNewswire/ -- Binance today announced $250,000 in humanitarian funding to support the frontline response to the ongoing...
ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens
The new intraocular lens combines an aspheric bitoric optic with a patented non-constant aberration design (ZO optic) on a fully preloaded, hydrophobic c-Loop platform to help deliver excellent visual outcomes and long-term stability for patients. JENA, Germany, June 11, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today the successful early clinical implantations...
Peer-reviewed publication shows that Lateral pharma’s SCP drugs for neuropathic pain act via the novel target LanCL1
MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The LanCL family of proteins are responsive to Lateral Pharma's Stressed Cell Protectant (SCP) drugs. The publication, titled "Lanthionine...
Cynosure Lutronic’s XERF™, Worldwide Adoption Accelerates, Now 3x Faster
Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North America leading the surge. SINGAPORE, June 11, 2026 /PRNewswire/ -- Cynosure Lutronic's XERF™, the world's first multifrequency monopolar RF device for non-invasive structural skin tightening, has surpassed 2,000 installed units worldwide in less than 2...
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Differentiated Advantages 1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable...
Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic...
Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were delivered by Timothy Garvey, MD, an internationally renowned expert in obesity and metabolic...
Manulife Asia Care Survey 2026: Independence as Asia’s New Legacy
From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved ones HONG KONG, June 11, 2026 /PRNewswire/ -- As longevity continues to rise across Asia, people are rethinking what it truly means to leave a legacy. Living longer no longer...
